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Previously, our group has used a B16-F10 melanoma
model to show that C-C chemokine receptor 5 (CCR5)
knockout (CCR5/) mice form fewer pulmonary me-
tastases than wild-type mice. This advantage can be
eliminated by injecting CCR5/ mice with wild-type
pulmonary mesenchymal cells before tumor injec-
tion. In this article, we present the mechanisms under-
lying this finding. First, we demonstrate that wild-type
mesenchymal cells migrate to CCL4 more efficiently in
vitro than CCR5/ cells. Wild-type mesenchymal cells
were also 3.6 (1.85 to 5.85) times more efficient than
CCR5/ cells at migrating into the lung after intrave-
nous injection (P < 0.01). The injection of wild-type but
not CCR5/ mesenchymal cells led to a 7.0  1.6 (P <
0.05)-fold induction of matrix metalloproteinase 9
(MMP9) in the host lung. Neither wild-type nor CCR5/
cells caused significant increases in MMP2, MMP3, or
MMP8. Inhibition of the gelatinase activity of MMP9
decreased the number of metastases and restored the
advantage that CCR5/ mice have over wild-type mice.
Further analysis showed that the CCR5 mesenchymal
cells expressed CD45 and CD13 but did not express
-smooth muscle actin. This phenotype is characteristic
of a subset of mesenchymal cells called fibrocytes. To-
gether, these data suggest a novel role for CCR5 in the
migration of pulmonary fibrocytes and the promotion
of metastasis. (Am J Pathol 2008, 173:253–264; DOI:
10.2353/ajpath.2008.070732)
More than 100 years ago, Stephen Paget suggested that
the viability of cancer cells at distant sites is determined
by both the cancer cell and the host tissue.1 His concept
of seed and soil has taken on prophetic significance with
the understanding of the tumor microenvironment and its
contribution to the growth and survival of metastatic can-
cer cells. More recently, this concept has been refined
with the description of the premetastatic niche.2 In short,
the host tissue prepares to accept metastases before the
entry of tumor cells into the circulation. According to
Kaplan and colleagues,3 this process is the result of the
influx of bone marrow-derived stromal cells. The migra-
tion of these stromal cells is mediated in part by chemo-
kines and chemokine receptors. In particular, these au-
thors find that the migration of stromal cells to the lung is
promoted by the chemokine CXCL12 and the chemokine
receptor CXCR4.3
Chemokines are small structurally related molecules
whose primary function is the recruitment of hematopoi-
etic cells.4 These molecules can be classified as homeo-
static or inflammatory.5 CXCL12 is a typical homeostatic
chemokine. It is constitutively produced, and it binds to
only one chemokine receptor, CXCR4.6 In contrast, the
expression of inflammatory chemokines is induced by
inflammatory stimuli. Such chemokines bind multiple re-
ceptors, and the receptors bind multiple chemokines.7
Cell migration is controlled by a combinatorial mix of
these chemokines and their receptors. Our study has
focused on the role of the inflammatory chemokine re-
ceptor C-C chemokine receptor 5 (CCR5) in the tumor
microenvironment.
We have observed that CCR5 knockout (CCR5/) mice
develop significantly fewer lung metastases than their wild-
type counterparts. The CCR5/ mice maintained this ad-
vantage even after transplantation with wild-type bone mar-
row. This experiment suggests CCR5 promotes metastasis
by its expression on nonhematopoietic stromal cells. This
hypothesis was tested by injecting wild-type pulmonary
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mesenchymal cells into CCR5/ mice before tumor injec-
tion. These mesenchymal cells increased the number of
metastases equal to the wild-type mice.8
Our current study provides the mechanism underlying
our previous findings. First, we establish that CCR5 is
required for the migration of pulmonary mesenchymal
cells into the lung. We go on to show that CCR5 is only
expressed on the CD45 mesenchymal cells. This sub-
set has a phenotype consistent with fibrocytes. Lastly, we
show that these pulmonary fibrocytes promote metasta-
sis through the induction of matrix metalloproteinase 9
(MMP9) in the host tissue. Thus, we establish a role for




C57BL/6J wild-type and C57BL/6-Tg (ACTB-EGFP)
1Osb/J enhanced green fluorescent protein transgenic
(EGFP-Tg) mice were purchased from Jackson Labora-
tories (Bar Harbor, ME). Chemokine receptor 5 knockout
(CCR5/) mice have been described previously.9,10
EGFP-Tg CCR5/ mice were generated by crossing
CCR5/ mice with EGFP-Tg mice as previously de-
scribed.11 All animals had been back crossed at least
eight generations and were housed in pathogen-free
conditions. All experiments were conducted using proto-
cols approved by Institutional Animal Care and Use Com-
mittee of the University of North Carolina at Chapel Hill.
Mesenchymal Cell Isolation
Pulmonary mesenchymal cells were isolated by the
method described by Schuler and colleagues12 with a
few modifications. In brief, the lungs were removed,
minced, and incubated in digestion media of 2% fetal calf
serum/RPMI (Life Technologies, Inc., Carlsbad, CA) with
1 mg/ml of collagenase A and 0.02 mg/ml of DNase I
(Boehringer Mannheim, Mannheim, Germany) for 35 min-
utes at 37°C with continuous rocking. After red cell lysis,
the resulting suspension was plated in 10% fetal calf
serum/Dulbecco’s modified Eagle’s medium (Life Tech-
nologies, Inc.) and cultured in 37°C with 5% CO2. The
media was replaced after 1 hour and every 3 to 4 days
thereafter. Cells were split 3:1 at 70 to 80% confluence.
Only cells from the second or third passage were used in
experiments. In vitro mesenchymal cells were viewed by
phase microscopy using an Olympus 1  70 inverted
microscope (Olympus America, Inc., Melville, NY). Im-
ages were captured with an Olympus QColor3 camera
and QCpture 2.56 software.
Flow Cytometry
Flow cytometry analysis was applied to mesenchymal
cells in culture and single cell lung suspensions. Non-
specific binding was blocked with anti-CD16/CD32 (BD
Biosciences Pharmingen, San Diego, CA) and 3% fetal
calf serum. The samples were incubated with the follow-
ing antibodies: anti-MHC Class II (AF6-120.1), anti-CD14
(rmC5-3), anti-CD 45 (31-F11), anti-CCR5 (C34-3448) (all
Pharmingen), anti-CD 13 (R3-63), anti-CD34 (MEC14.7)
(AbD Serotec, Oxford, UK), anti-F4/80 (C1: A3-1) (Cedar-
lane, Burlington, Canada), or anti-Thy1.1 (OX-70) (Ab-
cam, Cambridge, MA). Bone marrow and spleen cells
were used as positive controls. Data were collected on a
FACSCalibur (BD Biosciences, San Jose, CA) and ana-
lyzed using WinMDI version 2.8 software (Scripps Re-
search Institute, La Jolla, CA).
Mesenchymal cell survival was tested by growing cells to
70% confluency in six-well plates. At that point, the wells
were washed with phosphate-buffered saline (PBS); and
the cells were grown in serum-free media alone or with
CCL4 (50 ng/ml) or CCL5 (5 ng/ml) (Peprotech Inc., Rocky
Hill, NJ). After 24 or 48 hours, the cells were harvested and
stained with annexin V and 7-AAD (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions. Results
are expressed as the percentage of annexin V-positive cells
after excluding 7-AAD, annexin V cells.
Semiquantitative and Real-Time Reverse
Transcriptase-Polymerase Chain Reaction
(RT-PCR)
Total RNA was isolated from pulmonary mesenchymal
cells using the RNeasy Plus mini kit (Qiagen, Valencia,
CA) according to the manufacturer’s protocol. cDNA was
synthesized using M-MLV reverse transcriptase (Invitro-
gen) and random hexamers. RT-PCR was performed us-
ing ChromaTaq DNA polymerase (Denville Scientific,
Metuchen, NJ) and a Mastercycler thermocycler (Eppen-
dorf, Westbury, NY) with an annealing temperature of
56°C. Primer sequences and cycle number are given in
Table 1. The RT-PCR products were visualized using a
1.5% agarose gel; images were taken with the Gel Logic
200 imaging system and processed with Kodak 1D soft-
ware (Kodak, New Haven, CT).
Real-time RT-PCR was performed using SYBR green
and an ABI Prism 7900 real-time RT-PCR system (Ap-
plied Biosystems, Foster City, CA). The efficiency of each
primer pair was tested against serial dilutions of an am-
plicon-containing plasmid and the sample. Transcript
copy number was normalized against the absolute mRNA
amount as measured by the Qubit quantitation platform
(Invitrogen). In experiments in which the absolute mRNA
was less than 10 ng, samples were normalized by ex-
pression of succinate dehydrogenase complex, subunit
A, flavoprotein (SDHA). SDHA was used as a housekeep-
ing gene because transcript copy number in the mesen-
chymal cells had a high degree of correlation with the
amount of mRNA in a wide variety of culture conditions.
Immunohistochemistry
In vitro immunohistochemistry was performed by culturing
mesenchymal cells in Lab-Tek chamber slides (Nalge
Nunc International, Rochester, NY). These cells were
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fixed with 4% formalin and permeabilized with 0.2% Tri-
ton X-100 (Sigma-Aldrich, St. Louis, MO). Antibodies for
-smooth muscle actin (-SMA) (1A4) or isotype control
(Lab Vision, Fremont, CA) were added at 1:100 after
blocking with 10% goat serum. The antibody was de-
tected with an anti-mouse Ig antibody conjugated to Al-
exa 488 (Invitrogen). Images were captured using Olym-
pus B201 florescent microscope with camera (Olympus,
Center Valley, PA).
Western Blotting
Western blotting was performed as previously de-
scribed.13 In brief, mesenchymal cells were transferred
to six-well plates and cultured in serum-free media over-
night. The following day, the cells were treated with
CCL4; and cell lysates were harvested. The samples
were run on a 10% sodium dodecyl sulfate gel before
transfer to nitrocellulose. Phospho-Erk was detected us-
ing an antibody from Cell Signaling (Danvers, MA) diluted
1:1000. The secondary antibody was diluted 1:10,000.
Western blotting was also applied to lysates of mesenchy-
mal cells sorted by CD45 and Thy1.1. Antibodies for -SMA
(1A4) (Lab Vision) and CCR5 (C34-3448) (Pharmingen)
were also diluted 1:1000. Detection of -actin (H-196)
(Santa Cruz Biotechnology, Santa Cruz, CA) was used as a
loading control.
Migration Assay
Mesenchymal cells were cultured in serum-free condi-
tions overnight. Approximately 300 l of serum-free me-
dia with and without CCL4 was added to the wells of a
5.7-mm diameter, 300-l, 96-well ChemoTx plate (Neu-
roprobe, Gaithersburg, MD). Fifty l with 5  105 wild-
type or CCR5/ mesenchymal cells were added to the
filter. Chemokinesis was ruled out by adding CCL4 along
with the cells in selected wells. The plate was allowed to
incubate for 6 to 8 hours. Nonmigrating cells were then
removed with a rubber policeman. The filter was washed
with PBS and fixed with 4% paraformaldehyde. Nuclei on
the reverse side of the filter were counted after staining
with Vectashield with 4,6-diamidino-2-phenylindole (Vec-
tor Laboratories, Burlingame, CA). At least 30 high-pow-
ered fields were examined per well by an investigator
blinded to the treatment. Results are expressed as nuclei
per high-powered field.
In Vivo Experiments
Details for the melanoma metastasis model have been
previously described.8 In brief, 7.5  105 B16 F10 mel-
anoma cells (American Type Culture Collection, Rock-
ville, MD) in 200 l of PBS were injected via the tail vein.
Mice were euthanized 14 days later, and metastases
were counted after insufflation with Fekete’s destaining
solution.14 Reflected light images of the lung were taken
using the SteREO Lumar V12 scope and Axiovision soft-
ware (Zeiss Microscope Corporation, Thornwood, NY).
To assess migration of mesenchymal cells in vivo, cells
were isolated from wild-type and CCR5/ EGFP-Tg
mice. Of these EGFP expressing cells 4  105 were
suspended in 300 l of PBS and injected via the tail vein.
At days 1 and 5, a single cell suspension was formed
from the right lung and analyzed by flow cytometry. For-
ward and side scatter gates were based on cultured
mesenchymal cells before the injection. EGFP-Tg gate
(FL1) was set to exclude all cells from the lung of an
uninjected wild-type mouse. The data were reported as
the number of total cells multiplied by the percentage of
EGFP-Tg cells. The left lung was washed in cold PBS and
viewed with a SteREO Lumar V12 fluorescent microscope
and images were captured with Axiovision software
(Zeiss). In certain experiments, the above gating strategy
was used to sort single cell suspensions by EFGP ex-
pression using a MoFlo cytometer (Cytomation, Fort Col-
lins, CO).
Gelatinase inhibitor experiments were performed by
dissolving 1 mg of the cyclic peptide CTTHWGFTLC
(CTT) or the control peptide STTHWGFTLS (STT) (BioMol,
Plymouth Meeting, PA) in 1.5 ml of PBS. This solution was
added to an equal volume of mesenchymal cells at a
concentration of 2.67  106 cells/ml. The resulting mix-
ture was allowed to warm to 37°C before the injection. A
300-l injection resulted in a dose of 4  105 mesenchy-
mal cells with 100 g of CTT or STT. Migration of mes-
enchymal cells and the effect on metastasis was mea-
sured as described above.
Table 1. Primers Used for Semiquantitative and Real-Time RT-PCR
Gene Primers (forward, reverse) Amplicon size Cycles
CCR5 5-GAGGTGAGACATCCGTTCC 205 28
5-GACCATCATGTTACCCACAAAACC
SMA 5-ACTGGTATTGTGCTGGACTCT 169 26
5-CGGCAGTAGTCACGAAGGAAT
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Microarray Analysis
Raw mRNA expression data were generated from the
experiments of Altemeier and colleagues15 and down-
loaded from European Bioinformatics Institute, Heidel-
berg, Germany (accession: E-GEOD-2411; http://www.
ebi.ac.uk/microarray). In these experiments, six mice were
given 5 ng/g body weight of lipopolysaccharide by aspi-
ration; and six were given PBS only as a control. Total
RNA was harvested 4 to 6 hours later and hybridized onto
separate Affymetrix GeneChips Mouse Genome 430A
2.0. Raw data were normalized using an index of SDHA,
GAPDH, PyrCarbMur-1, and actin.
Statistics
Unless otherwise stated, data are presented as the mean
of measurements taken from three or more separate ex-
periments. Statistical error for these means is presented
as 1 SEM. Confidence intervals were determined using
a 60% trimmed mean. P values were determined by
Mann-Whitney test,16 and values 0.05 were considered
significant. The Bonferroni correction was applied to the
microarray experiments.
Results
Mesenchymal Cells Isolated from the Lungs of
Wild-Type and CCR5 Knockout Mice Are
Phenotypically Similar
In our previous work, we increased the number of metas-
tases in CCR5/ mice by injecting them with pulmonary
mesenchymal cells from wild-type mice. These mesen-
chymal cells were isolated by culturing a suspension of
lung cells in 10% Dulbecco’s modified Eagle’s medium.
Because mesenchymal cells isolated from CCR5/
lungs did not increase metastasis, we began this inves-
tigation by comparing mesenchymal cells from wild-type
and CCR5/ mice.
Pulmonary mesenchymal cells from wild-type and
CCR5/ mice cells were microscopically similar. Each
population had pleomorphic appearance with cells rang-
ing from spindle shaped to large and flat (Figure 1A). This
microscopic equivalence was corroborated by flow cy-
tometry, which showed similar forward and side scatter
profiles of the mesenchymal cells from both mice (Fig-
ure 1B). Wild-type and CCR5/ pulmonary mesenchy-
mal cells were also composed of similar subpopula-
tions as defined by CD45 expression. The CD45
subpopulation from both mice expressed CD13 but not
CD14, CD34, CD86, or MHC class II (Figure 1C). Fur-
thermore, no difference was found in the size of this
subpopulation (P  0.38).
Wild-type and CCR5/ mesenchymal cells also had
similar CD45-negative cell subpopulations. Neither wild-
type nor CCR5/ CD45 cells expressed CD13, CD34,
CD86, and MHC class II. These cells could be separated
into two subpopulations by Thy1.1.17 However, the size of
Figure 1. Wild-type and CCR5/ pulmonary mesenchymal cells are phe-
notypically similar. A: Phase contrast microscopy of wild-type and CCR5/
mesenchymal cells. B: Forward and side scatter patterns of ungated wild-type
and CCR5/ mesenchymal cells by flow cytometry. C: Contour graphs of
CD45 (x axis) and Thy1.1 (y axis) expression on wild-type and CCR5/
mesenchymal cells as measured by flow cytometry. The percentage for each
gate is based on the mean of six samples. Single color histograms for CD45
mesenchymal cells are given below each contour graph. These are repre-
sentative graphs from the six samples. Original magnifications, 100.
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Thy1.1 and Thy1.1 subpopulations were similar in the
wild-type and CCR5/ mice (P  0.89 and P  0.66,
respectively). Taken together, neither CD45 nor Thy1.1
expression can explain differences in metastasis after
injection into CCR5/ mice.
Flow cytometry analysis was also used to detect con-
taminating macrophages by measuring CD11c, CD14,
and F4/80. Less than 2% of wild-type and CCR5/ cells
expressed CD11c and CD14, and less than 5% of cells
expressed F4/80. No statistical differences were found
between the wild-type and CCR5/ mice. It is highly
unlikely that macrophages were experimentally signifi-
cant because injection of wild-type macrophages did not
increase metastasis in CCR5/ mice (data not shown).
Pulmonary Mesenchymal Cells from Wild-Type
and CCR5/ Mice Show No Difference in
Activation or Survival in Vitro
Given the similar cell surface phenotypes of the wild-type
and CCR5/ mesenchymal cells, we examined differ-
ences in activation by measuring -SMA. -SMA is a
marker of myofibroblasts, which has been associated
with tumor progression.18,19 Immunohistochemical stain-
ing for -SMA was similar in the wild-type and CCR5/
cells (Figure 2A). This observation was corroborated by
semiquantitative RT-PCR (Figure 2C). Therefore, the abil-
ity of wild-type cells to promote metastasis could not be
explained by differences in -SMA expression.
Differences in metastasis could possibly be explained
by differences in survival of wild-type and CCR5/ mes-
enchymal cells. We tested this hypothesis by culturing
wild-type and CCR5/ cells in serum-free conditions for
24 to 48 hours. The CCR5 agonists CCL4 and CCL5 were
added to final concentrations of 50 and 5 ng/ml, respec-
tively. Using Annexin V as a marker of cell death, we
found the average survival in all conditions was 89.8 
1.2% for wild-type cells and 89.8  0.% for CCR5/
cells. There were no significant differences between wild-
type and CCR5/ cells in any conditions (Figure 2B).
Wild-Type Pulmonary Mesenchymal Cells
Respond to CCL4 in Vitro
Having established morphological similarities between
wild-type and CCR5/ pulmonary mesenchymal cells,
we turned our attention to the function of CCR5. First, we
verified the expression of CCR5 by semiquantitative RT-
PCR (Figure 2D). Surface expression was confirmed by
flow cytometry analysis (see Figure 5A). Both methods
demonstrated the presence of CCR5. Next, we tested the
ability of CCR5 to induce a downstream signal by mea-
suring activation of the MAP kinase pathway after stimu-
lation with CCL4.20 MAP kinase activation was detected
by Western blotting for phospho-ERK at 30, 60, and 120
minutes after adding CCL4 (Figure 2E). We verified the
function of MAPK signal transduction by comparing the
chemotaxis of wild-type and CCR5/ pulmonary mes-
enchymal cells. Wild-type cells migrated toward CCL4 at
concentrations of 25 and 50 ng/ml (Figure 2F). No signif-
icant chemotaxis was seen using concentrations of 0 or
100 ng/ml of CCL4. Thus, wild-type mesenchymal cells
demonstrated a dose response similar to hematopoietic
Figure 2. Wild-type pulmonary mesenchymal cells differ from CCR5/ by
their response to CCL4. A: Fluorescent microscopy of wild-type and CCR5/
mesenchymal cells revealing similar staining for -SMA. B: Measurement of
cell death by annexin V staining demonstrating no difference in survival of
wild-type and CCR5/ cells. Samples were tested in serum-free media alone
or with CCL4 (50 ng/ml) or CCL5 (5 ng/ml). Cell debris was excluded with
7-AAD (n  4). C: Semiquantitative RT-PCR demonstrating the presence of
-SMA in wild-type and CCR5/ mesenchymal cells. The gel shows cDNA
from three separate experiments. The number of cycles for each reaction was
chosen to assure linear amplification of the transcript. SDHA was chosen as
a loading control based on its high degree of correlation with the amount of
mRNA in a wide variety of conditions. D: Semiquantitative RT-PCR demon-
strating the expression of CCR5 in wild-type pulmonary mesenchymal cells
(n  3). E: Western blotting for phospho-ERK showing a response to CCL4
(50 ng/ml) in wild-type mesenchymal cells. F: Chemotaxis assay establishing
migration of wild-type but not CCR5/ mesenchymal cells to CCL4. Cells
were added to a 5.7-m chemotaxis plate and incubated for 6 to 8 hours with
varying concentrations of CCL4. Migrating cells were detected on the reverse
side of the filter using fluorescent microscopy after fixation and staining with
4,6-diamidino-2-phenylindole. Thirty or more high-powered fields were
counted (n  3). Original magnification, 100.
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cells. No such response was seen in CCR5/ mesen-
chymal cells.
Wild-Type Mesenchymal Cells Migrate More
Efficiently than CCR5/ Cells in Vivo
We tested the relevance of this in vitro chemotaxis by
comparing the migration of wild-type and CCR5/ mes-
enchymal cells into the lung. This comparison was ac-
complished by isolating pulmonary mesenchymal cells
from wild-type and CCR5/ EGFP-Tg mice and then
injecting 4  105 of these cells into the tail vein of wild-
type or CCR5/ mice. Twenty-four hours later, a single
cell suspension was formed from the lung and analyzed
by flow cytometry. Given the low number of injected cells,
flow cytometry gates were set to exclude cells from un-
injected control mice (Figure 3A). This gating strategy
detected 95% of EGFP-Tg mesenchymal cells taken
directly from culture. Furthermore, EGFP-Tg wild-type
and EGFP-Tg CCR5/ cells had similar EGFP fluores-
cent intensity (Figure 3B).
Using this strategy, we found that wild-type mesenchy-
mal cells were 3.6 (1.85 to 5.85) times more efficient in
their ability to migrate into the lung than CCR5/ cells
(P  0.003) (Figure 3C and Table 2). The migratory
capacity of wild-type cells did not depend on the pres-
ence of CCR5 in the recipient. Equivalent numbers of
wild-type EGFP-Tg cells were detected in wild-type and
CCR5/ recipients. These results were confirmed by
fluorescent stereomicroscopy (Figure 3E).
We established the kinetics of mesenchymal cell mi-
gration by measuring the number of EGFP-Tg cells 5
days after injection. In these experiments, mice were
injected with B16-F10 tumor cells 1 day after mesenchy-
mal cell injection. These experiments showed a decrease
of 84.7% (72.0 to 96.4%) in the recoverable number of
mesenchymal cells (P  0.007) (Figure 3D). In other
words, wild-type pulmonary mesenchymal cells were
found 1 day after injection, but they did not persist in the
lung throughout the long term.
MMP9 Expression Is Induced in Mesenchymal
and Host Cells
These results established the presence of wild-type mes-
enchymal cells in the lungs of CCR5/ mice at the time
that the B16-F10 melanoma cells are injected. The next
question was how such a small number of these CCR5
expressing mesenchymal cells can promote metastasis.
Stimulation of CCR5 has been linked to the production of
MMP9 in a mouse model of emphysema.21 Because
MMP9 has also been correlated with metastasis in mela-
noma,22 we used real-time RT-PCR to measure the ex-
pression of MMP9 in the EGFP-Tg mesenchymal cells
isolated 24 hours after intravenous injection. We found
that transcription of MMP9 increased by 6.3  2.2-fold
when compared to uninjected mesenchymal cells (P 
0.05). In contrast, MMP2 and MMP3 transcripts fell below
detection by real-time RT-PCR indicating down-regula-
tion of these genes after injection into CCR5/ mice
(Figure 4A). Transcription of MMP8 was not significantly
changed by injection. Data for CCR5/ EGFP-Tg mes-
enchymal cells was not included because the number of
recovered cells was too small for reliable measurement.
We also measured changes in MMP transcription in the
EGFP host cells after injection with mesenchymal cells.
The transcription of MMP9 was significantly increased
(7.0  1.6, P  0.05) in the host after the injection of
wild-type mesenchymal cells (Figure 4A). Injection with
CCR5/ mesenchymal cells led to a small increase in
MMP9 (2.4  0.5, NS); however, this change was not
statistically significant. Transcription of MMP2, MMP3,
and MMP8 did not significantly change in the host cells
after injection with wild-type or CCR5/ mesenchymal
cells.
Inhibition of Gelatinase Activity Suppresses the
Ability of Wild-Type Mesenchymal Cells to
Increase Metastasis in CCR5/ Mice
Next, we determined if this increase in MMP9 transcrip-
tion contributed to the ability of wild-type mesenchymal
cells to promote metastasis. In these experiments, MMP9
activity was inhibited with the addition of gelatinase pep-
tide inhibitor CTTHWGFTLC (CTT).23,24 Treatment with
the altered peptide STTHWGFTLS (STT) was used as the
control. In each experiment the peptide and the cells
were combined and warmed to body temperature before
injection. In Figure 4B, we demonstrated that treatment
with CTT had no affect on the migration of wild-type
mesenchymal cells into CCR5/ mice. Therefore, differ-
ences in metastases between CTT- and STT-treated mice
were not attributable to the inability of CTT-treated cells to
migrate into the lung. However, CTT did inhibit the ability
of wild-type mesenchymal cells to promote metastasis
(Figure 4, C and D). CCR5/ mice injected with STT
(control)-treated wild-type mesenchymal cells developed
50.6% more metastases than CCR5/ mice injected
with CTT-treated cells (116.5  12.3 versus 77.3  9.1,
P  0.05). CCR5/ mice injected with CTT-treated wild-
type mesenchymal cells developed the same number of
metastases as CCR5/ mice injected with CCR5/
cells (77.3  9.1 versus 81.0  7.2, NS).
Wild-Type Pulmonary Fibrocytes Promote
Metastasis in CCR5/ Mice
The experiments discussed thus far have used unsorted
pulmonary mesenchymal cells. To better understand the
properties of these cells, we sorted these cells using
CD45 and Thy1.1 expression. Of the three subpopula-
tions, only the CD45 population expressed CCR5 (Fig-
ure 5A). Furthermore, the CD45 cells did not express
-SMA (Figure 5B). Taken together, the CD45 cells
were phenotypically similar to fibrocytes.
CD45 fibrocytes also differed from CD45 fibroblasts
in MMP expression. When compared to the unsorted
mesenchymal cell population, the CD45 cells ex-
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Figure 3. Wild-type mesenchymal cells migrate more efficiently in vivo than CCR5/ cells. A: Gating strategy for the detection of injected EGFP-Tg
mesenchymal cells. R1 includes viable cells based on FSC/SSC. R2 excludes all EGFP-Tg-negative cells based on flow cytometry analysis of an uninjected
lung. These gates detect more than 95% of all EGFP-Tg cells before injection (middle). Migrating mesenchymal cells are detected in R2 after injection
(bottom). B: Expression of EGFP-Tg is equivalent in wild-type and CCR5/ mesenchymal cells. Representative FSC/SSC and FSC/EGFP-Tg dot plots of
wild-type and CCR5/ EGFP-Tg mesenchymal cells. C: More wild-type than CCR5/ cells are detected 24 hours after intravenous injection. Bar graphs
show the number of EGFP-Tg cells recovered from the right lung as determined by the percentage of EGFP-Tg cells times the number of cells isolated. The
number of animals for each experiment is given above the graph. D: The number of detected wild-type fibroblasts decreases throughout time. A similar
strategy as described in C was applied to mice 1 and 5 days after injection. E: Fluorescent microscopic images of the left lungs of mice from C using a SteREO
Lumar V dissecting scope. Scale bar  1 mm. Original magnifications, 42.
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pressed MMP2 1.8  0.9 times higher and MMP3 2.1 
0.55 times higher than the unsorted population. MMP9
was not detected. On the other hand, CD45 fibrocytes
expressed MMP8 at 3.3  0.48 times higher and MMP9
at 5.1  0.68 times higher than the unsorted mesenchy-
mal cells. MMP2 and MMP3 were not detected (Figure
5C). This pattern of high MMP9 and MMP8 with low
MMP2 and MMP3 was similar to that seen in the EGFP
cells after injection into a CCR5/ mouse (Figure 4A).
These observations suggested that the increase in
MMP9 in the EGFP-Tg mesenchymal cells was not attrib-
utable to an induction of MMP9. Instead, this increase
was attributable to a selection of CCR5 fibrocytes. This
assertion was further strengthened by the observation
that the addition of CCL4 or CCL5 to the pulmonary
mesenchymal cells did not lead to an increase in MMP9
(Figure 5D) Therefore, we concluded that the metastasis-
producing properties of these fibrocytes was their ability
to induce MMP9 in the host tissue.
CCR5 Ligands Are Expressed in the Lung
We identified the CCR5 agonists in an unmanipulated
mouse lung using a data mining approach. Raw mRNA
expression data from wild-type B6 mice were down-
loaded from the European Bioinformatics Institute (see
Materials and Methods) and normalized to an index of 10
probes.15 We considered a gene to be detectable if the
normalized mRNA value was 0.2. This value was ap-
proximately equivalent to a raw expression value of 300.
Using the above criteria, we were able to detect 15 of 32
chemokines (Table 3). This set included the CCR5 li-
gands CCL4, CCL5, and CCL8. Ligands for other fibro-
cyte-associated chemokine receptors were also present
including CCR1 (CCL6, CCL5, CCL9), CCR2 (CCL8),
CCR7 (CCL21, CCL19), CXCR1 (CXCL7, CXCL16),
CXCR3 (CXCL4, CXCL10), and CXCR4 (CXCL12). Only
ligands for CCR3 and CCR9 were absent in the unstimu-
lated lung. We compared the baseline chemokine expres-
sion pattern to chemokine expression after the mice had
been challenged with lipopolysaccharide. This analysis re-
vealed seven additional detectable chemokines. Three of
these seven are ligands for fibrocyte-associated chemokine
receptors: CCL22 (CCR4), CCL2 (CCR2), and CCL3
(CCR1, CCR5). Of the CCR5 ligands, three had significant
fold increases of mRNA expression including CCL3 (6.8 
1.6), CCL4 (2.4  0.3), and CCL5 (2.7  0.4).
Discussion
For this study, we have altered the premetastatic stroma
of the lungs of CCR5/ mice by injecting them with
Figure 4. Inhibition of MMP9 blocks the ability of
wild-type mesenchymal cells to promote metasta-
sis in CCR5/ mice. A: Transcription of MMP9
increases in migrating mesenchymal cells and host
tissue. EGFP-Tg wild-type and CCR5/ cells
were injected into CCR5/ mice. Twenty-four
hours later, EGFP-Tg and non-EGFP-Tg cells were
sorted; and mRNA was isolated from each group.
Real-time RT-PCR was used to measure the ratio of
MMP transcripts from EGFP-Tg cells before and
after injection. Copy number was normalized to
SDHA. Non-EGFP-Tg cells were compared to an
average of sorted cells from six noninjected
CCR5/ lungs. The sample of CCR5/ EGFP-Tg
cells was not included (see text). B: Inhibition of
gelatinase activity does not affect the migration of
wild-type fibroblasts. The bar graph shows the
number of wild-type EGFP-Tg mesenchymal cells
isolated after injection. The black bar is the num-
ber of cells treated with the gelatinase inhibitor
CTT; the hatched bar is the number of cells treated
with the control peptide STT. C: Inhibition of ge-
latinase results in fewer metastases in CCR5/
mice. CCR5/ mice were injected with wild-type
mesenchymal cells treated with the inhibitor (CTT)
or control peptide (STT). Twenty-four hours later,
7.5  105 melanoma cells were injected via the tail
vein. Metastases in these groups were compared to
CCR5/ mice injectedwithCCR5/ mesenchymal
cells. Two weeks after tumor injection the numbers
ofmetastaseswere counted. D: Photomicrographs of
a sample of CCR5/ lungs used in C.









WT EGFP-Tg WT (day 1) 7.4  0.49 69,000  4100 28  3 0.04  0.007% 3.0  0.77
WT EGFP-Tg WT CCR5/ (day 1) 8.4  1.3 90,000  700 40  4 0.04  0.002% 3.8  0.69
CCR5/ EGFP-Tg CCR5/ (day 1) 6.9  0.48 87,000  7300 10  1 0.01  0.003% 0.9  0.21
WT EGFP-Tg CCR5/ (day 5) 6.8  0.66 47,000  3100 3  1 0.01  0.001% 0.4  0.09
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wild-type mesenchymal cells. Analysis of EGFP-Tg wild-
type cells demonstrated the viability of these cells at the
time of hematogenous seeding of tumor cells. Further-
more, we have shown that the wild-type cells both ex-
press CCR5 and respond to CCR5 ligands and that this
expression is required for entry into the lung. We also
showed that CCR5 was expressed only in the CD45,
CD13 subpopulation of the mesenchymal cells. Be-
cause the cells of this subpopulation are referred to as
fibrocytes,25,26 we concluded that fibrocytes contribute
to the premetastatic niche.
The capacity of the fibrocyte to increase metastasis
was established using injections of only 60,000 CD45
cells. This profound effect on metastasis is best ex-
plained by the ability of the fibrocyte to induce MMP9 in
the host tissue. One explanation for the induction of
MMP9 is that fibrocytes facilitate the invasion of other
MMP9-expressing cells. For example, MMP9 on the fibro-
cyte can activate the chemotactic factors S100A8 and
S100A9.27 These proteins are induced within the
premetastatic niche by the distant tumor28 and can en-
hance the influx of monocytes. MMP9 also releases vas-
cular endothelial growth factor (VEGF),29 which may act
on bone marrow-derived hematopoietic progenitor cells
drawn into the premetastatic niche.2,3 Monocytes30 and
VEGF receptor hematopoietic progenitor cells31 can
increase expression of MMP9. Furthermore, fibrocytes
may directly increase MMP9 by the production of fibro-
blast growth factor-132 and hepatocyte growth factor.33
Our study offers further evidence for the importance of
MMP9 in the premetastatic stages of metastasis.34 MMP9
may precondition the stroma by activating transforming
growth factor (TGF)-.35 In the later stages of cancer, this
cytokine can support tumor progression by promoting
angiogenesis and inhibiting immune surveillance.36 How-
ever, in the premetastatic setting, TGF-’s effects are
likely on the stroma. Specifically, TGF- can transform
fibrocytes,37 fibroblasts,38 and even alveolar epithelial
cells,39 into -SMA-expressing myofibroblasts. More direct
evidence linking MMP9 to the formation of myofibroblasts
has been seen in models of lung33 and liver fibrosis.40
Whether MMP9 works directly or indirectly, myofibroblasts
have been associated with cancer growth41 and a poorer
prognosis.18
This study does raise questions about the origin of our
injected fibrocytes. Earlier definitions of fibrocytes in-
cluded bone marrow-derived cells42 that expressed ColI,
CD11b, CD13, CD34, CD45, MHC class II, and CD86.43
Later definitions recognized that many of these markers
may be down-regulated.37,44 Thus, our CD45, CD13,
CCR5, SMA cells are consistent with fibrocytes. How-
ever, we have previously shown that the transfer of wild-
type bone marrow into CCR5/ mice does not promote
metastasis.8 This result would suggest that these fibro-
cytes are not bone marrow-derived.
One explanation is that these pulmonary fibrocytes are
distinct from bone marrow fibrocytes. In this model, the
pulmonary fibrocytes are present at the inception of me-
tastasis and decline throughout the first 5 days. In con-
trast, bone marrow-derived fibrocytes increase through-
out time.45 These cells are recruited not via CCR5 but by
CXCR4 and CCR7.43 In fact, this recruitment may be the
result of CXCL12 production by the resident fibroblasts.46
These observations would suggest two separate stromal
cells axes: resident fibrocytes that facilitate invasion and
depend on inflammatory chemokines and recruited fibro-
cytes that promote growth of established disease and
depend on constitutive chemokines. The alternative ex-
planation for the failure of wild-type bone marrow to in-
crease metastasis in CCR5/ mice is attributable to the
radioresistant nature of resident fibrocytes and the slow
accumulation of these cells in host tissues after trans-
plant. In this model, the prometastatic effects of fibro-
cytes are more evident after the direct inoculation of
these cells.
Several mouse studies have used bone marrow trans-
plant techniques to demonstrate the dependence of fi-
brocytes on various chemokine receptors. For example,
fibrocytes require CCR1 in wound healing43 and renal
fibrosis,47 CCR2 in pulmonary fibrosis,25 CCL3/CCR5
Figure 5. Wild-type pulmonary fibrocytes pro-
mote metastasis in CCR5/ lungs. A: Wild-type
fibrocytes express CCR5. Representative histo-
grams for CCR5 gated on CD45 mesenchymal
cells. Isotype control is shown as the unfilled con-
tour (n  6). B: Wild-type and CCR5/ fibrocytes
do not express -SMA. A representative Western
blot showing expression of -SMA in the CD45
fraction of the mesenchymal cells but not in the
CD45 fraction (fibrocytes) (n  3). C: Wild-type
pulmonary fibrocytes express MMP8 and MMP9.
mRNA was harvested from wild-type pulmonary
mesenchymal cells sorted by CD45 and Thy1.1. Real-
time RT-PCR was used to measure the ratio of MMP
transcripts in the sorted population compared with
unsorted cells. The graph depicts the mean of four
experiments. D: Pulmonary mesenchymal cells do
not increase MMP9 in response to CCL4 or CCL5.
Wild-type and CCR5/ mesenchymal cells were
cultured in serum-free conditions overnight. The fol-
lowing day CCL4 (50 ng/ml), CCL5 (5 ng/ml), or no
chemokine (control) was added. mRNA was har-
vested 6 hours later. Real-time RT-PCR was used to
measure a ratio of MMP9 transcripts in the chemo-
kine-treated cells versus the untreated cells. Copy
number was normalized to mRNA amount. The
graph depicts the mean of these ratios (n  6).
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in bleomycin-induced lung injury,48 and CCL21/CCR7 in
idiopathic interstitial pneumonia34 and renal fibrosis.49 In
all of these studies, chemokines are induced by a stim-
ulus (eg, wounding, bleomycin, uretral obstruction, and
so forth). Although baseline expression of the CCR5 li-
gands is adequate to establish wild-type fibrocytes in the
lungs of wild-type and CCR5/ mice, it does not lead to
a dramatic turnover in pulmonary fibrocytes after synge-
neic transplant. Hence, fibrocyte populations are more
reflective of the host than the donor mice.
If the induction of MMP9 by CCR5 fibrocytes is the
reason that wild-type mice develop more metastases
Figure 6. A model for the role of inflammatory and constitutive chemokines in metastasis. A: The quiescent stroma begins with a low risk for accommodating
metastasis. Pulmonary fibrocytes enter this area in a process facilitated by CCR5. The migration of fibrocytes may be further enhanced by inflammation or by
changes induced by the distant tumor. B: Pulmonary fibrocytes induce the expression of MMP9. This metalloproteinase can support the developing premetastatic
niche by promoting the expression and activation of VEGF and TGF-. TGF- will further advance this niche by the conversion of fibroblasts into myofibroblasts.
Eventually, this niche becomes vulnerable to invasion by circulating tumor cells. C: Entering tumor cells interact with the resident stroma to produce constitutive
chemokines such as CXCL12. This signal promotes the influx of circulating fibrocytes via CCR7. These cells become incorporated into the tumor and produce
factors that promote the growth of the tumor nidus. D: The process continues resulting in a metastatic tumor.
Table 3. Pulmonary Chemokine Expression: Before and After LPS Stimulation
Chemokine Receptor Control* SEM LPS stimulated SEM Fold change†
CXCL15 CXCR5 5.09 0.212 4.70 0.153
CCL6 CCR1 1.63 0.056 1.61 0.110
CCL21 CCR7 0.73 0.042 0.58 0.026
CXCL7 CXCR1, CXCR2 0.58 0.108 0.94 0.207
CXCL4 CXCR3 0.50 0.057 0.63 0.087
CCL5 CCR1, CCR5 0.43 0.042 1.13 0.060 2.7  0.4
CXCL12 CXCR4 0.42 0.010 0.33 0.015
CCL9 CCR1 0.33 0.093 0.97 0.086
CXCL14 0.28 0.026 0.30 0.036
CXCL16 CXCR1, CXCR2 0.28 0.018 0.42 0.017 1.5  0.2
CCL19 CCR7 0.22 0.011 0.57 0.043 2.6  0.3
CCL17 CCR4 0.22 0.061 0.73 0.041 3.3  1.2
CCL8 CCR2, CCR5 0.22 0.054 0.19 0.005
CCL4 CCR5 0.21 0.010 0.52 0.040 2.4  0.3
CXCL10 CXCR3 0.21 0.103 3.25 0.238 15.3  5.6
CCL20 CCR6 0.17 0.020 0.53 0.036 3.1  0.6
CXCL13 CXCR5 0.16 0.021 0.34 0.038
CXCL1 CXCR2 0.15 0.035 1.47 0.122 9.7  3.2
CX3CL1 CX3CR 0.13 0.005 0.14 0.005
CCL24 CCR3 0.13 0.005 0.13 0.020
CCL22 CCR4 0.11 0.051 0.28 0.027 2.5  0.1
CXCL9 CXCR3 0.11 0.014 0.24 0.031
CCL2 CCR2 0.10 0.015 0.29 0.092 2.8  1.5
CXCL2 CXCR2 0.08 0.001 1.25 0.001 16.2  4.5
CCL28 CCR3, CCR10 0.07 0.008 0.07 0.033
CCL3 CCR1, CCR5 0.05 0.006 0.37 0.007 6.8  1.6
CCL7 CCR1, CCR3, CCR5 0.05 0.006 0.09 0.005
CCL12 CCR2 0.04 0.001 0.08 0.007
CCL11 CCR3 0.04 0.001 0.08 0.001
CCL25 CCR9 0.03 0.001 0.03 0.001
CXCL11 CXCR3 0.02 0.003 0.03 0.021
CXCL5 CXCR2 0.02 0.002 0.15 0.034
Bold: chemokine receptors associated with fibrocytes44; underlined: expressed chemokines.
*Affymetrix array raw expression data normalized to a set of index genes.
†P  0.002 (fold change is only given for statistically significant increases).
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than CCR5/ mice, one would expect wild-type mice to
have higher baseline levels of MMP9 expression. How-
ever, MMP9 levels are not significantly different between
the two strains (data not shown). One possible explana-
tion for this apparent discrepancy is the inability of real-
time PCR to detect small, loco-regional differences. A
small increase in MMP9 may have a profound effect on
metastasis because several positive feedback loops ex-
ist to amplify its effects. Alternatively, injection of wild-
type fibrocytes may overcome another anti-metastatic
effect found in the stroma of CCR5/ mice. In either
case, our results support the conclusion that wild-type
fibrocytes are more efficient in establishing a premeta-
static niche than CCR5/ fibrocytes.
Our results can be synthesized with the results of
others using the model illustrated in Figure 6. Small num-
bers of pulmonary fibrocytes enter the host tissue. This
process is facilitated by CCR5 and may be accelerated in
the setting of inflammation. After invasion, the fibrocytes
contribute to the premetastatic niche through the induc-
tion of MMP9 and the expression of fibronectin. MMP9
expression leads to the releases of VEGF and activation
of TGF-, which transforms resident fibroblasts into myo-
fibroblasts. In this environment, tumor cells are able to
invade and thrive. After the invasion of cancer cells,
chemotactic factors are produced by the interaction of
tumor cells and stroma. These chemokines lead to the
recruitment of other fibrocytes. These fibrocytes become
activated and begin producing factors that support the
growth of the tumor nidus. The process continues and a
life-threatening metastasis is formed.
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